2016;24(5):218-223. 295. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127(5):634-640. 296. Jones WS, Hellkamp AS, Halperin J, et al. Ef cacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial brillation: insights from ROCKET AF. Eur Heart J. 2014;35(4):242-249. 297. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/ APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial brillation. Europace. 2018;20(1):e1-e160. 298. Di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial brillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation. 2014;129(25):2638-2644. 299. Cappato R, Marchlinski FE, Hohnloser SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial brillation. Eur Heart J. 2015;36(28): 1805-1811. 300. Calkins H, Willems S, Gerstenfeld EP, et al. Uninterrupted dabigatran versus warfarin for ablation in atrial brillation. N Engl J Med. 2017;376(17):1627-1636. 301. Essebag V, Healey JS, Ayala-Paredes F, et al. Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: the BRUISE CONTROL-2 trial. Am Heart J. 2016;173:102- 107. 1196 Evidence-Based Medicine [ 1 5 4 # 5 C H E S T N O V E M B E R 2 0 1 8 ] 302. Cardoso R, Knijnik L, Bhonsale A, et al. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial brillation catheter ablation. Heart Rhythm. 2018;15(1):107-115. 303. 